SRT 1720 dihydrochloride

Name: SRT 1720 dihydrochloride
Brand: MedChemExpress
SKU: HY-15145A
Rating: 5.0 (36 reviews)

Cat. No.: HY-15145A Purity: 99.13%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

SRT 1720 dihydrochloride is a selective and orally active activator of SIRT1 with an EC₅₀ of 0.10 μM, and shows less potent activities on SIRT2 and SIRT3.

For research use only. We do not sell to patients.

SRT 1720 dihydrochloride Chemical Structure

CAS No. : 2468639-77-0

Size	Price	Stock	Quantity

Free Sample (0.1 - 0.5 mg)		Apply Now
Solid + Solvent
10 mM * 1 mL in DMSO ready for reconstitution	USD 72	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 72	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 60	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 90	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 190	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 330	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 550	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 36 publication(s) in Google Scholar

Other Forms of SRT 1720 dihydrochloride:

SRT 1720 In-stock
SRT 1720 monohydrochloride In-stock

32 Publications Citing Use of MCE SRT 1720 dihydrochloride

: SRT 1720 dihydrochloride purchased from MedChemExpress. Usage Cited in: Exp Eye Res. 2023 Apr 2;109464. [Abstract]; SRT1720 (1 μM; 1 h) reverses UVA (Using ultraviolet A)-inhibited expression of PGC-1α, NRF2 and TFAM in B4G12 cells.

: SRT 1720 dihydrochloride purchased from MedChemExpress. Usage Cited in: Exp Eye Res. 2023 Apr 2;109464. [Abstract]; SRT1720 (1 μM; 1 h) effectively decreases the levels of cell death and ROS accumulation in the UVA (Using ultraviolet A)-irradiated B4G12 cells.

: SRT 1720 dihydrochloride purchased from MedChemExpress. Usage Cited in: Hypertension. 2016 Nov;68(5):1191-1199. [Abstract]; SRT1720 rescues the downregulation of SIRT1 activity and protein expression in the aortas of KL^+/– mice. A, Representative Western blot bands of Acetyl-P53 and total P53 and the quantification of SIRT1 activity. Data are expressed as the ratio of acetyl-p53/total P53. B, Representative Western blot bands and quantitative analysis of SIRT1 protein expression in aortas. Protein expression is normalized to β-actin, and the relative expression calculated as the fold change relative

: SRT 1720 dihydrochloride purchased from MedChemExpress. Usage Cited in: Toxicol Lett. 2016 Dec 15;264:1-11. [Abstract]; The HNF1α, FXR, Mrp2 and Bsep protein levels are decreased after EE administration and significantly increased by SRT1720 in a dose dependent manner, which is in accordance with the mRNA levels.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Sirtuin Isoform Specific Products:

View All Isoforms

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

SRT 1720 dihydrochloride is a selective and orally active activator of SIRT1 with an EC₅₀ of 0.10 μM, and shows less potent activities on SIRT2 and SIRT3^[1].

IC₅₀ & Target

SIRT1

0.10 μM (EC₅₀)

In Vitro

SRT 1720 dihydrochloride effectively decreases the acetylation of p53 in cells even in the absence of SIRT1, and this is attributed to inhibition of histone acetyltransferase p300^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

SRT 1720 (10, 30, 100 mg/kg, p.o.) dihydrochloride treatment significantly reduces fasting blood glucose to near normal levels in Lep^ob/ob mice^[1].
SRT 1720 dihydrochloride has ability to protect against the negative effects of diet-induced obesity in mice, and has a connection to metabolic adaptation in fatty acid and oxidative metabolism through downstream targets of SIRT1 such as PGC1α and FOXO1^[2].
SRT 1720 (50-100 mg/kg, p.o.) dihydrochloride, during emphysema development attenuates elastase-induced airspace enlargement and lung function impairment as well as reduces arterial oxygen saturation in WT mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

542.48

Formula

C₂₅H₂₅Cl₂N₇OS

CAS No.

2468639-77-0

Appearance

Solid

Color

Brown to orange

SMILES

O=C(NC1=C(C=CC=C1)C2=CN3C(SC=C3CN4CCNCC4)=N2)C5=NC6=C(N=C5)C=CC=C6.[H]Cl.[H]Cl

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 85 mg/mL (156.69 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 12.5 mg/mL (23.04 mM; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.8434 mL	9.2169 mL	18.4339 mL
5 mM	0.3687 mL	1.8434 mL	3.6868 mL
10 mM	0.1843 mL	0.9217 mL	1.8434 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Purity & Documentation

Purity: 99.13%

Select Batch:

Data Sheet (283 KB) SDS (251 KB)

COA (258 KB) HNMR (364 KB) RP-HPLC (268 KB) LCMS (132 KB)

Handling Instructions (2659 KB)

References

[1]. Milne JC et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007 Nov 29;450(7170):712-6 [Content Brief]

[2]. Baur JA, et al. Are sirtuins viable targets for improving healthspan and lifespan?,Nat Rev Drug Discov. 2012 Jun 1;11(6):443-61 [Content Brief]

[3]. Yao H, et al. SIRT1 protects against emphysema via FOXO3-mediated reduction of premature senescence in mice.,J Clin Invest. 2012 Jun 1;122(6):2032-45. [Content Brief]

[4]. Gao D, et al. Activation of SIRT1 Attenuates Klotho Deficiency-Induced Arterial Stiffness and Hypertension by Enhancing AMP-Activated Protein Kinase Activity. Hypertension. 2016 Nov;68(5):1191-1199. [Content Brief]

[5]. Lahusen TJ, et al. SRT1720 induces lysosomal-dependent cell death of breast cancer cells. Mol Cancer Ther. 2015 Jan;14(1):183-92. [Content Brief]

Animal Administration
^[1]

Mice: Nine week old C57BL/6 male mice are fed a high fat diet (60% calories from fat) until their mean body weight reach approximately 40 g. The mice are then divided into test groups (6-10 per group). SRT1460 (100 mg/kg), SRT 1720 (100 mg/kg), SRT501 (500 mg/kg) and BRL49653 (5 mg/kg) are administered once daily via oral gavage. The vehicle used is 2% HPMC + 0.2% DOSS. Individual mouse body weights are measured twice weekly. At 2, 4, 6, 8 and 10 weeks of dosing a fed blood glucose measure is taken and after 5 weeks of treatment an IPGTT is conducted on all mice from each of the groups. After 10 weeks of treatment, an ITT is conducted. Statistical analysis is completed using the JMP program. Data are analyzed by a one way ANOVA with comparison to control using a Dunnett’s Test. A p value < 0.05 indicates a significant difference between groups.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

[1]. Milne JC et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007 Nov 29;450(7170):712-6 [Content Brief]

[2]. Baur JA, et al. Are sirtuins viable targets for improving healthspan and lifespan?,Nat Rev Drug Discov. 2012 Jun 1;11(6):443-61 [Content Brief]

[3]. Yao H, et al. SIRT1 protects against emphysema via FOXO3-mediated reduction of premature senescence in mice.,J Clin Invest. 2012 Jun 1;122(6):2032-45. [Content Brief]

[4]. Gao D, et al. Activation of SIRT1 Attenuates Klotho Deficiency-Induced Arterial Stiffness and Hypertension by Enhancing AMP-Activated Protein Kinase Activity. Hypertension. 2016 Nov;68(5):1191-1199. [Content Brief]

[5]. Lahusen TJ, et al. SRT1720 induces lysosomal-dependent cell death of breast cancer cells. Mol Cancer Ther. 2015 Jan;14(1):183-92. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	1.8434 mL	9.2169 mL	18.4339 mL	46.0846 mL
	5 mM	0.3687 mL	1.8434 mL	3.6868 mL	9.2169 mL
	10 mM	0.1843 mL	0.9217 mL	1.8434 mL	4.6085 mL
	15 mM	0.1229 mL	0.6145 mL	1.2289 mL	3.0723 mL
	20 mM	0.0922 mL	0.4608 mL	0.9217 mL	2.3042 mL
DMSO	25 mM	0.0737 mL	0.3687 mL	0.7374 mL	1.8434 mL
	30 mM	0.0614 mL	0.3072 mL	0.6145 mL	1.5362 mL
	40 mM	0.0461 mL	0.2304 mL	0.4608 mL	1.1521 mL
	50 mM	0.0369 mL	0.1843 mL	0.3687 mL	0.9217 mL
	60 mM	0.0307 mL	0.1536 mL	0.3072 mL	0.7681 mL
	80 mM	0.0230 mL	0.1152 mL	0.2304 mL	0.5761 mL
	100 mM	0.0184 mL	0.0922 mL	0.1843 mL	0.4608 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.